Interpretive FAQ | Sustainogaine Outcomes

Reading duration

How durable are reported abstinence periods?

A stated abstinence period is a description of what was reported at a particular point in follow-up. It does not, by itself, establish a durable effect for a broader population. The useful questions are: who was followed, for how long, how many people were unavailable at follow-up, and whether the outcome was independently verified.

Longer follow-up can be informative, but duration alone does not remove uncertainty. A case report may describe one person’s account or a small selected group, while a prospective cohort can set a follow-up plan in advance and account for the people who do not complete it. The long-term outcomes overview provides a wider frame for reading those differences without turning them into treatment conclusions.

Follow-up quality

What can a case record tell you?

Useful interpretation starts with the denominator, the timing, and the method used to verify outcomes.

What do attrition and selection bias mean here?

Attrition occurs when people cannot be reached or do not respond at follow-up. Selection bias can occur when the documented participants differ from those who are missing from the record. If losses are not clearly counted, a favorable result can appear more common than it is. The definition of selection bias helps explain why a visible set of follow-up accounts may not represent everyone initially observed.

How should single-dose and repeated-dose reports be separated?

They should be treated as different exposure descriptions. A report should specify whether it concerns one administration, repeated administrations, or a sequence involving other interventions. Without that separation, a later outcome cannot be cleanly attributed to one event or compared fairly across reports.

Which outcomes are reliably measured?

Reports may document self-reported substance use, stated timing of follow-up, or a person’s own account of change. Those fields are more interpretable when the method of collection and the number of participants assessed are explicit. A clear denominator and a defined observation window matter as much as the outcome wording.

What is commonly missing?

Toxicology confirmation, mortality ascertainment, cardiac screening, systematic adverse-event capture, and complete accounting for people lost to follow-up are often absent or inconsistently presented. The aftercare and confounder questions help readers distinguish a documented outcome from the many influences that may surround it.

Confidence upgrades

What data would strengthen confidence?

Confidence increases when study design reduces ambiguity before results are known. Randomized controlled trials can compare groups under a specified protocol, while prospective cohorts can define eligibility, follow-up intervals, adverse-event collection, and outcome verification in advance. The evidence hierarchy described by the National Library of Medicine is a useful reminder that study design affects how strongly an observation can be interpreted.

For long-term ibogaine follow-up cases, more informative records would state the initial sample, all dose exposure details, co-occurring care, retention at each interval, verification methods, and all safety-related outcomes captured. That is a different standard from a compelling individual narrative.

“A follow-up account can be meaningful to the person described while still leaving causal and population-level questions open.”

Contextual image for evaluating follow-up details in long-term ibogaine case records

Visual accompaniment to a practical checklist for long-term ibogaine follow-up cases

Practical reading

Which details deserve the closest attention?

When reading a case report, look for the fields that allow a reader to see both the result and its limits. This is practical guidance for evaluating information, not medical advice and not an encouragement to pursue any intervention. Broader context about the organization’s purpose is available in Sustainogaine Outcomes’ stated approach.

A defined starting group, including how many people entered the record and who was followed later.
Dates or intervals for follow-up, with a clear distinction between planned and opportunistic contact.
Precise exposure reporting that distinguishes single-dose, repeated-dose, and co-occurring interventions.
Outcome methods, including whether reports rely on self-report, toxicology, records, or another stated source.
Safety fields: adverse events, cardiac screening information, mortality ascertainment, and missing follow-up data.

Missing information is not proof of a negative outcome; it is an uncertainty that should remain visible. For context on why controlled study methods use specified comparators and outcome plans, see the ClinicalTrials.gov overview of clinical studies.

Keep the record and the inference separate.

Follow-up cases can add detail to an uncertain picture. Their value is clearest when readers can see what was observed, how it was measured, and what remains unmeasured.

Independent treatment-location context